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Abstract
Kisspeptins (Kp), peptide products of the Kisspeptin-1 (KISS1) gene are endogenous ligands for a G protein-coupled receptor
54 (GPR54). Previous findings have shown that KISS1 acts as a metastasis suppressor in numerous cancers in humans.
However, recent studies have demonstrated that an increase in KISS1 and GPR54 expression in human breast tumors
correlates with higher tumor grade and metastatic potential. At present, whether or not Kp signaling promotes breast
cancer cell invasiveness, required for metastasis and the underlying mechanisms, is unknown. We have found that
kisspeptin-10 (Kp-10), the most potent Kp, stimulates the invasion of human breast cancer MDA-MB-231 and Hs578T cells
using Matrigel-coated Transwell chamber assays and induces the formation of invasive stellate structures in three-
dimensional invasion assays. Furthermore, Kp-10 stimulated an increase in matrix metalloprotease (MMP)-9 activity. We also
found that Kp-10 induced the transactivation of epidermal growth factor receptor (EGFR). Knockdown of the GPCR
scaffolding protein, b-arrestin 2, inhibited Kp-10-induced EGFR transactivation as well as Kp-10 induced invasion of breast
cancer cells via modulation of MMP-9 secretion and activity. Finally, we found that the two receptors associate with each
other under basal conditions, and FRET analysis revealed that GPR54 interacts directly with EGFR. The stability of the
receptor complex formation was increased upon treatment of cells by Kp-10. Taken together, our findings suggest a novel
mechanism by which Kp signaling via GPR54 stimulates breast cancer cell invasiveness.
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Introduction
Kisspeptins (Kp) are peptide products of the metastasis-
suppressor KISS1 gene and are the endogenous ligands for G
protein-coupled receptor 54 (GPR54), a Gq/11-coupled receptor
[1,2,3]. Activation of GPR54 results in the activation of
phospholipase C, protein kinase C (PKC), and the mitogen-
activated protein kinase cascade (MAPK) [4]. The KISS1 gene
codes for a hydrophobic 145 amino acid sequence, which is
subsequently cleaved into a 54 amino acid sequence, which in turn
may be cleaved by furin or prohormone convertases (deduced by
the presence of pairs of basic residues flanking this sequence) into
even shorter biologically active peptides (10, 13, 14 amino acids
long), collectively referred to as Kp. The shortest and most active
KISS1 gene product is Kisspeptin-10 (Kp-10), a 10-residue peptide
[3]. In numerous cancers such as melanoma, pancreatic cancer,
and gastric carcinoma, KISS1/GPR54 signaling is anti-metastatic
[5,6]. GPR54 activity has been shown to repress matrix
metalloprotease-9 (MMP-9) activity, increase production of tissue
inhibitor of matrix metalloprotease-1 (TIMP-1), inhibit cell
migration, and increase activity of focal adhesion kinase (FAK),
leading to formation of excessive focal adhesions and stress fibres
[3,4]. Additionally, activation of GPR54 by Kp has been shown to
inhibit cell motility, proliferation, invasion, chemotaxis and
metastasis [2,3,7,8,9].
The role of GPR54 in breast cancer has been difficult to discern.
Recent studies have shown that the expression of KISS1 and
GPR54 correlates with breast tumor progression and poor patient
prognosis [10]. Indeed, patients who died of breast cancer had the
highest expression of KISS1 mRNA [11]. Furthermore, GPR54 and
KISS1 mRNA expression is significantly elevated in tumors
compared to normal mammary tissue [10]. The high KISS1 and
GPR54 mRNA levels positively correlated with shorter relapse-free
survival [10]. However, whether or not Kp actually promote
breast cancer invasiveness and the underlying mechanisms that
may be involved are unknown.
The epidermal growth factor receptor (EGFR), a member of the
ErbB family of receptor tyrosine kinases, is an important
therapeutic target for several epithelial tumors, including breast
cancer. EGFR is overexpressed in human breast tumors and the
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survival, proliferation, angiogenesis and metastasis [12]. Upon
stimulation, EGFR is known to autophosphorylate tyrosine
residues on the C-terminal domain of its dimerized binding
partner. These residues then serve as docking sites for a number of
proteins, including Grb2/Sos, c-cbl, Src, PI3K (Phosphatidylino-
sitol 3-kinases) and phospholipase Cc (PLCc), leading to activation
of the MAPK pathway and Akt/protein kinase B. The
internalization of EGFR has further been shown to be required
for mitogenic signaling via the activation of MAPKs, resulting in
transcriptional changes leading to increased migration, invasion,
and metastasis [13,14].
EGFR can be transactivated by GPCRs in a variety of cell types
including tumor cells [15,16,17,18]. Defined as the phosphoryla-
tion of ERK1/2 in response to an unrelated agonist, transactiva-
tion appears to require EGFR kinase activity, the proteolytic
release of EGFR ligands, and a cascade of secondary messengers,
including a rise in cytosolic Ca
2+ concentration, activation of
PKC, and tyrosine kinases such as Src and PYK2 [19,20].
Recently, it has been shown that the GPCR scaffolding protein b-
arrestin 2 promotes EGFR transactivation via interactions with Src
in vascular smooth muscle cells [19].
The aim of this study was to investigate for the first time
whether or not Kp directly stimulate breast cancer cell
invasiveness and the underlying mechanism(s) involved. The
results obtained establish a functional role for Kp signaling in
promoting breast cancer cell motility and invasion, two critical
processes required for metastasis, via cross-talk with EGFR.
Methods
Materials and DNA Constructs
Human Kp-10 was purchased from Phoenix Pharmaceuticals
(Burlingame, CA). The following were purchased from Sigma Aldrich
(St. Louis, MO): human, recombinant epidermal growth factor (EGF),
Protein G-sepharose beads, anti-FLAG mouse and rabbit antibodies.
Rabbit polyclonal phospho-Src family Tyr416 antibody was obtained
from Cell Signaling Technology, MA. Antibody against Kp-10 was a
generous gift from Dr. Alain Caraty (Laboratoire de Physiologie de la
Reproduction, France) [21]. FLAG-tagged GPR54 and pEGFP-N1-
EGFR were obtained from Dr. Andy Babwah.
Cell Culture
Cell lines were purchased from ATCC (Manassas, VA) and
cultured at 37uC with 5% CO2. Human invasive breast carcinoma
MDA-MB-231, Hs578T, T47D and C8161 cells were cultured in
RPMI 1640 (Invitrogen, Burlington, Ontario, Canada) supple-
mented with 10% (v/v) fetal bovine serum (FBS, Sigma). Human
embryonic kidney (HEK)-293 cells were cultured in Eagle’s
minimum essential medium (MEM; Invitrogen, Burlington,
Ontario, Canada), supplemented with 10% (v/v) FBS (Sigma)
and 50 mg/mL gentamicin. HEK cells were transiently transfected
with FLAG-GPR54 and EGFR-GFP using a modified calcium
phosphate method [22]. Fresh medium was added to the cells 18 h
after transfections and the cells were allowed to recover for 8 h
before being reseeded onto either coverslips for receptor
internalization assays, 35 mm glass-bottomed culture plates for
confocal microscopy, or 100 mm culture plates for co-immuno-
precipitation experiments. Expression of receptors was determined
in each experiment using immunofluorescence.
Stable Transfections and Gene Knockdowns
MDA-MB-231 cells (5610
6) were transfected with FLAG-
GPR54 constructs (MDA-MB-231 FLAG-GPR54) (25 mg) by
electroporation (250 V, 950 mF) using the Gene Pulser Xcell (Bio-
Rad, Mississauga, Ontario, Canada) according to the manufactur-
er’s instructions. A heterogeneous population of stable transfectants
was selected by using media containing 750 mg/mL G418
(Invitrogen) and expression verified by immunostaining or Western
blot for FLAG-GPR54. Gene knockdown of b-arrestin 2 in MDA-
MB-231 cells was achieved using shRNA construct (OriGene
Technologies, sequence 59-CAGAATCTTCCATGCTCCGTCA-
CACTGCA-39, designated shRNA 1) as we have previously
described [23]. A heterogeneous population of stable transfectants
was obtained via puromycin (1 mg/mL) selection. Knockdown of b-
arrestin 2 was verified by Western blot analysis.
Cell Migration and Invasion Assays
Transwell filters (8 mm pores) were placed into a 24-well plate
containingeitherserum-freemediaormediasupplementedwith10%
FBS. For cell invasion assays, the tops of filters were coated with
50 mL of diluted phenol-red free Matrigel (9.4 mg/mL stock, BD
Biosciences) in serum-free RPMI 1640. Cells were serum-starved for
4 h. MDA-MB-231 (4.0610
4), C8161 (4.0610
4) or T47D (1.5610
5)
cells were plated in the upper chamber in either serum-free media or
serum-free media supplemented with 10 nM or 100 nM Kp-10 and
incubated for 20 h. For studies involving EGFR inhibitor AG1478
( C a l b i o c h e m ,E M DB i o s c i e n c e sI n c . ,L aJ o l l a ,C A ) ,c e l l sw e r ep r e -
treated with AG1478 (500 nM) for 30 min as previously described,
and seeded in serum-free RPMI with or without Kp-10 (10 nM) in
addition to AG1478 (500 nM) or vehicle control (DMSO) [24]. Cells
were then fixed with a 20% acetone:80% methanol solution and
nuclei stained with 0.1% Hoechst 33258 (Invitrogen) and counted on
the bottom of the filters. Two replicates were conducted for each
condition, and 10 random fields in each replicate were chosen and
counted using an Olympus IX-71 inverted microscope. Results are
presented as a ratio of cells that migrated relative to cells that
migrated or invaded in control conditions (cells seeded in serum-free
media and migrating towards 10% (v/v) FBS in RPMI). Results are
from at least three independent experiments.
Three-Dimensional Invasion Assays
For three-dimensional cell invasion assays, cells were seeded in a
1:1 dilution of phenol red-free Matrigel and culture medium at
2.5610
6 cells/mL on Matrigel-coated 35 mm glass-bottomed culture
dishes (Mattek, Ashland, MA). Cultures were overlaid with culture
medium and grown for up to 4 days in the presence or absence of
10 nM Kp-10. Cell colonies were scored blindly as being either
stellate or spheroidal after growth in Matrigel. A colony was deemed
stellate if one or more projections from the central sphere of cells were
observed. Overlaying medium was supplemented with 750 mg/mL of
G418 for MDA-MB-231 cells stably transfected with FLAG-GPR54.
Images were taken on an IX-81 microscope (Olympus, Center
Valley, PA) using InVivo Analyzer Suite (Media Cybernetics).
MTT Cell Viability Assays
MTT reduction assays (Roche Applied Science) were conducted
according to the protocol of the manufacturer, as previously
described [23]. Briefly, cells were incubated with 0.5 mg/mL of
MTT labeling reagent for 4 h and subsequently solubilized for 12
to 16 h. Absorbance of the supernatant was read at 575 nm using
a Wallac Victor3 V plate reader (Perkin-Elmer) and a reference
reading taken at 750 nm.
Zymographic Analysis of Secreted Metalloproteases
Zymographic analysis was performed as previously described
[25]. MBA-MD-231 cells were serum starved (24 h). Cells to be
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AG1478 (Calbiochem) for 30 minutes prior to stimulation. Cells
were then stimulated for 24 h with respective reagents. Following
stimulation, conditioned media were collected on ice and briefly
centrifuged to remove any cellular debris. Supernatant was
concentrated in Ultracel-10K Amicon centrifugal filter unit
(Millipore). Samples were collected and concentrated conditioned
media was resolved in an SDS/polyacrylamide gel containing
1 mg/mL gelatin. The gels were then washed in Novex
Zymogram Developing Buffer (Invitrogen) for 30 min to remove
the SDS, and incubated overnight at 37uC to allow for enzymatic
digestion of the gelatin. For control experiments, gels were
incubated in 16 Novex developing buffer containing 5 mM
EDTA for 24 h at 37uC. After incubation, gels were stained using
Coomassie blue, destained, and visualized using the VersaDoc
imaging system (Bio-Rad).
Scratch Assays for Cell Motility
MDA-MB-231 cells were seeded into a 12-well dish in RPMI
1640 supplemented with 10% FBS and allowed to grow to
confluency. Cells were then serum-starved in RPMI for 4 h and
scratched with sterile pipette tips followed by treatment with
10 nM or 100 nM Kp-10 in RPMI supplemented with 10% FBS.
Cells were allowed to migrate into the scratch for 12 h and
visualized every hour using an IX-81 microscope (Olympus).
Distance travelled (in mm) was then measured over the course of
the 12 h, using duplicates for each condition and five fields per
duplicate. Data was analyzed using ImagePro software (Media
Cybernetics) and graphed versus time.
EGFR Immunoprecipitation
MDA-MB-231 or Hs578T cells were serum-starved for 24 h
and then stimulated with various ligands at the indicated
concentrations for the indicated times. Cell fractions were
solubilized in lysis buffer (20 mM HEPES, 150 mM NaCl,
1.5 mM MgCl2, 1 mM EDTA, 2 mM Na3VO4, 1 mM NaF,
10% glycerol, 1% Triton X-100, protease inhibitors). Lysates
(850 mg of total protein) were used for immunoprecipitation
studies. EGFR was immunoprecipitated using a polyclonal anti-
EGFR antibody (1:100, Upstate Millipore) and protein G-
sepharose beads (Sigma) over-night at 4uC. Immunoprecipitated
proteins were separated by SDS-PAGE and phosphorylation of
EGFR was examined using a mouse monoclonal anti-phosphotyr-
osine antibody (PY-20, 1:1000, Santa Cruz) and visualized by
enhanced chemiluminescence. Western blots were then reprobed
with rabbit polyclonal anti-EGFR antibody (1:5000, Upstate
Millipore) to assess total EGFR. EGFR expression from cell lysates
(50 mg of total protein) was examined using a rabbit polyclonal
EGFR antibody. To determine the mechanism of EGFR
transactivation, cells were grown to 80% confluency and serum-
starved for 24 h, prior to stimulation with 10 nM Kp-10 for the
indicated time points. EGFR was immunoprecipitated as de-
scribed above.
Src Phosphorylation
MDA-MB-231 b-arrestin 2 knockdown stable cell line and
scrambled controls were serum-starved for 24 h and then
stimulated with 10 nM Kp-10 for the indicated time intervals.
Cell fractions were solubilized in lysis buffer (20 mM HEPES,
150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 2 mM Na3VO4,
1 mM NaF, 10% glycerol, 1% Triton X-100, protease inhibitors).
Lysates (100 mg of total protein) were separated by SDS-PAGE
and phosphorylation of Src was examined using a rabbit
polyclonal anti-phosphotyrosine antibody (phospho-Src family
Tyr416, 1:1000, Cell Signaling Technology) and visualized by
enhanced chemiluminescence.
Confocal Microscopy
MDA-MB-231 FLAG-GPR54 (stable cells) were transfected
with EGFR-EGFP and were serum-starved for 4 h. Cells were
plated on cover-slips and FLAG-GPR54 receptors were labelled
with a monoclonal anti-FLAG antibody (1:500, Sigma) for 45 min
at 4uC, warmed to 37uC and treated with Kp-10 or EGF (as
indicated in the figure legends). For all experiments, cells were
subsequently fixed and permeabilized with 4% paraformaldehyde
followed by 0.2% Triton X-100 and FLAG receptors were labelled
by anti-mouse AlexaFluor-546 (1:1200, Invitrogen). Nuclei were
stained with 0.1% Hoechst 33258 (Invitrogen). To detect Kp-10
presence in MDA-MB-231 cells, cells were stained using and anti-
rabbit polyclonal Kp-10 antibody (1:750), followed by labelling by
anti-rabbit AlexaFluor-555 (1:1200, Invitrogen). Cells were
visualized using a Zeiss LSM-510 META laser scanning
microscope (Zeiss, Oberkochen, Germany).
Co-immunoprecipitation and Immunoblot
HEK 293 cells were transfected with empty FLAG vector
(pFLAG-A1) and EGFR-EGFP or FLAG-GPR54 and EGFR-EGFP
using modified calcium phosphate method [22]. Forty eight hours
following transfection, cells were serum-starved for 4 h and then
stimulated with Kp-10 (10 or 100 nM) and EGF (100 ng/mL) for the
indicated times. Cell fractions were solubilized in lysis buffer (20 mM
HEPES, 150 mM NaCl, 1.5 mM MgCl2,1 %T r i t o nX - 1 0 0 ,
protease inhibitors). Cell lysates (500 mg of total protein) were used
for co-immunoprecipitation studies. FLAG-GPR54 was immuno-
precipitated using a mouse monoclonal anti-FLAG antibody and
protein G-Sepharose beads (Sigma) over-night at 4uC. Immunopre-
cipitated proteins were separated by SDS-PAGE and EGFR-GFP
expression examined using a mouse monoclonal anti-GFP antibody
(1:2000, Upstate Millipore) and visualized by enhanced chemilumi-
nescence, following the manufacturer’s protocol.
Fluorescence Resonance Energy Transfer (FRET)
FRET wasperformed using the sensitized emissionmethod onan
Olympus FV1000 confocal microscope accordingto the one photon
method described by Elangovan et al. and the sensitized emission
FRET method outlined in the FV10 Olympus software [26]. HEK
293 cells transiently transfected with GPR54-ECFP and EGFR-
EGFP seeded on collagen-coated 35 mm glass-bottom culture
dishes (Mattek Corp Ashland, MA) were serum starved for 4 h and
then imaged live at 37uC with 660 Plan Apochromat 1.42 oil
objectivelensand36zoom.Sevenimageswereacquiredofallthree
specimens (single-labeled donor, single-labeled acceptor and
double-labeled specimen) under the exact same conditions (36
zoom,102461024 pixels,same laserpower,optics, gain,integration
time). The single-labeled acceptor specimen was excited by donor
and acceptor wavelengths and both single-scan images were
acquired in the acceptor channel. The single-labeled donor
specimen was scanned at the donor excitation wavelength and the
image was acquired twice, once in the donor channel and the
second time in the acceptor channel. The double-labeled specimen
wasscanned at the acceptor wavelength anda single scan imagewas
acquired in the acceptor channel; next it was excited by the donor
wavelength and images were acquired in the acceptor and donor
channels. Using the Precision FRET (PFRET) algorithm donor and
acceptor spectral-bleed through were removed, variations in
fluorophore expression levels were corrected, the energy transfer
efficiency (E%) was calculated, and the distance between donor and
acceptor molecules using the same set of cells used for FRET
Kisspeptin Promotes Breast Cancer Invasion
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21599imaging [26]. The Fo ¨rster distance for the ECFP-EGFP pair is 4.7–
4.9 nm. To quantify ourresults,fiveregions of interest (ROIs)of the
same exact size were placed at different areas of the plasma
membrane in each image, and at approximately the same locations
in the subsequent time points in each experiment. The mean
PFRET efficiency foreachareawas then determined.Themeans6
SEM are shown for values obtained for the number of independent
experiments indicated in the figure legends.
Statistical Analysis
One-way analysis of variance (ANOVA) with a Dunnett’s post-
hoc test or Student’s t-test was performed using GraphPad Prism 4
(GraphPad Software, Inc.). Differences with P,0.05 were
considered statistically significant.
Results
Kp-10 promotes migration and invasion of breast cancer
cells
We first sought to determine whether Kp-10 stimulates invasion
of breast cancer cells using standard Transwell chamber Matrigel-
invasion assays. Human invasive breast cancer MDA-MB-231
cells or Hs578T cells were seeded in either serum-free media or
serum-free media containing Kp-10 and allowed to invade across
Figure 1. Kp-10 stimulates breast cancer cell invasion. (A) Invasion of MDA-MB-231 and Hs578T cells was measured by Matrigel-coated
Transwell chamber assays. Kp-10 treatment (10 nM Kp-10) significantly increased the number of cells invading towards 10% serum. Student’s T-test:
*, P,0.05 when compared to cells invading towards 10% serum. Data from at least three independent experiments. (B) Kp-10 enhances MDA-MB-231
invasion in a dose-dependent manner. Cell invasion was measured by Matrigel-coated Transwell chamber assays as described above. One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P,0.05. Data from at least three independent experiments. (C) Kp-10 stimulates breast
cancer cell migration of MDA-MB-231 cells as was measured by Transwell chamber assays. One-way ANOVA followed by Dunnett’s multiple
comparison test: *, P,0.05. Data from at least three independent experiments. (D) Kp-10 does not act as a chemoattractant to stimulate breast cell
migration. Migration of MDA-MB-231 cells was measured by Transwell chamber assays. Data from at least three independent experiments. (E)
Localization of Kp-10 in MDA-MB-231 cells. Kp-10 immunoreactivity is seen at the cell surface and distributed intracellularly. Lower panel: cells shown
at a higher magnification. Scale bar, 10 mm in top panels and 10 mm in bottom panels. Data from at least three independent experiments.
doi:10.1371/journal.pone.0021599.g001
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that Kp-10 (10 nM) significantly stimulated cell invasion towards
10% serum in both cell-types, compared to the corresponding
untreated cells (Fig. 1A). A dose-dependent increase in MDA-MB-
231 cell invasion was obtained when treated with various
concentrations of Kp-10, with a maximal response obtained using
100 nM Kp-10 (Fig. 1B). All further experiments were done using
either 10 nM or 100 nM Kp-10, as reported in other studies
[27,28,29]. Kp-10 (10 nM) also stimulated MDA-MB-231 cell
migration towards 10% serum (Fig. 1C). We found that Kp-10
does not act as a chemoattractant to stimulate breast cell migration
(Fig. 1D) or invasion (data not shown). To determine whether or
not MDA-MB-231 cells express Kp-10, these cells were immuno-
stained for endogenous Kp-10 using a rabbit anti-Kp-10 antibody
Figure 2. Kp-10 increases breast cancer cell invasive stellate structure formation in 3D cultures by stimulating MMP-9 activity. (A)
MDA-MB-231 cells were seeded in a mixture of Matrigel and 10% serum medium. Treatment of cells with 10 nM Kp-10 results in a significant increase
in stellate structure formation on days 2 and 3 when compared to untreated cells. Student’s t-test: *, P,0.05 compared to untreated cells invading in
Matrigel. Data from at least three independent experiments. (B) Treatment of MDA-MB-231 FLAG-GPR54 cells with 10 nM Kp-10 significantly
promotes enhanced stellate structure formation in 3D cultures at day 3 when compared to untreated cells. Student’s t-test: *, P,0.05 compared to
untreated stable cell line invading in Matrigel. No statistical difference in degree of stellate structure formation was observed between MDA-MB-231
stably expressing vector, pFlag cells (untreated) and MDA-MB-231 FLAG-GPR54 cells (untreated). Data from at least three independent experiments.
(C) Treatment of Hs578T cells with 10 nM Kp-10 significantly enhanced stellate structure formation at days 2 and 3 when compared to untreated cells.
Student’s t-test: *, P,0.05 compared to untreated cells invading in Matrigel on their respective days. Data from at least three independent
experiments. Line, mean percentage of stellate colonies versus total colonies counted that day; Scale bar, 100 mm in (A) and (B), 40 mm in (C). (D) Kp-10
stimulates MMP-9 secretion and activity in breast cancer cells. Representative zymograph from seven independent experiments.
doi:10.1371/journal.pone.0021599.g002
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de la Reproduction, France) [21]; we and others have shown that
KISS1 and GPR54 are expressed in these cells [13,28]. We found
that Kp-10 positive immunostaining at the cell surface membranes
and localized intracellularly in the MDA-MB-231 breast cancer
cell line (Fig. 1E).
Kp-10 promotes breast cancer cell invasion in three-
dimensional cultures
Both normal and malignant breast cells can be cultured in
reconstituted extracellular matrix as a three-dimensional (3D)
model, mimicking the in vivo micro-environment [23]. We have
previously demonstrated that MDA-MB-231 cells express endog-
enous GPR54 [11,27]. However, since a robust antibody to detect
endogenous GPR54 is lacking, we stably expressed FLAG-GPR54
in these cells to easily detect the tagged receptor for biochemical
analysis. Treatment of MDA-MB-231 (Fig. 2A), MDA-MB-231
FLAG-GPR54 (Fig. 2B), and Hs578T cells (Fig. 2C) with 10 nM
Kp-10 resulted in an increase in the formation of stellate
structures, when compared to untreated cells or cells expressing
vector control, with a significant increase observed at day 2 and
day 3 in MDA-MB-231, day 3 in MDA-MB-231 FLAG-GPR54,
and day 2 and day 3 in Hs578T cells. This indicates that Kp-10
treatment of breast cancer cells increases the formation of invasive
structures.
Kp-10 stimulates MMP-9 secretion and activity
In order to determine how Kp-10 promotes breast cancer cell
invasion, we employed the use of zymographic analysis of matrix
metalloprotease secretion. We found that treatment of MDA-MB-
231 cells that express endogenous GPR54 [27] with either 10 or
100 nM of Kp-10 increases the secretion of MMP-9 (Fig. 2D),
revealing for the first time that Kp-10 signaling via GPR54 in
breast cancer cells stimulates the secretion of MMP-9.
Kp-10 promotes motility of breast cancer cells
In order to visualize whether or not Kp-10 stimulates motility of
breast cancer cells in real-time, we performed scratch assays as
described [30]. We observed that Kp-10 treatments (10 nM or
100 nM) significantly enhance the distance travelled by the MDA-
MB-231 cells over time, when compared to cells seeded only in
Figure 3. Kp-10 stimulates breast cancer cell motility. Treatment
with both 10 nM and 100 nM Kp-10 enhances distance closed by MDA-
MB-231 cells in a scratch assay. Scale bar, 100 mm. a, P,0.05 for 10 nM
Kp-10 when compared to untreated control cells seeded in serum; b,
P,0.05 for 100 nM Kp-10 when compared to untreated control cells
seeded in serum. Bars represent mean distance travelled in mm 6 SEM.
Data from five independent experiments.
doi:10.1371/journal.pone.0021599.g003
Figure 4. Kp-10 stimulates transactivation of EGFR in breast
cancer cells. (A) MDA-MB-231 and (B) Hs578T cells were treated with
10 nM Kp-10 for the indicated time points and then solubilized in lysis
buffer. Kp-10 treatment resulted in a significant increase in EGFR
phosphorylation (One-way ANOVA followed by Dunnett’s multiple
comparison test: *, P,0.05). Basal levels of phosphorylated EGFR are
regarded as 1. Columns represent relative fold change of phosphory-
lated EGFR as compared to basal level 6 SEM. Data from three
independent experiments. (C) Kp-10 stimulates MMP-9 secretion and
activity in breast cancer cells via an EGFR-dependent mechanism.
Treatment with AG1468 inhibits Kp-10-dependent MMP-9 secretion.
Representative zymograph from three independent experiments. (D)
Kp-10 (10 nM) treatment significantly increases MDA-MB-231 FLAG-
GPR54 cell invasion. Treatment with AG1478 (500 nM) significantly
decreases invasion of MDA-MB-231 FLAG-GPR54 cells (b, P,0.05). a,
P,0.05 compared to untreated MDA-MB-231 FLAG-GPR54 cells
invading towards media with 10% serum. b, P,0.05 compared to cells
invading towards media with 10% serum. c, P,0.05 compared to Kp-10-
treated MDA-MB-231 FLAG-GPR54 invading towards media with 10%
serum. Columns represent the mean percentage of cells invaded as
compared to control cells invading towards media with 10% serum 6
SEM. Data from three independent experiments.
doi:10.1371/journal.pone.0021599.g004
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10 stimulates not only breast cancer cell invasion, but also
enhances their motility.
GPR54 transactivates EGFR in breast cancer cells to
regulate cell invasion
Since our data revealed that Kp-10 does not act as a
chemoattractant to stimulate breast cell migration (Fig. 1D), we
investigated whether or not GPR54 may crosstalk with EGFR to
regulate breast cancer cell invasion. We initially determined
whether or not Kp-10 transactivates this tyrosine kinase receptor.
Lysates from Kp-10-treated cells were examined for phosphory-
lated EGFR by immunoblotting as described [31,32]. We
observed that treatment of MDA-MB-231 cells with 10 nM Kp-
10 resulted in an increase in the phosphorylation of EGFR,
reaching peak activation at 5 min post-treatment (Fig. 4A).
Treatment of Hs578T cells with 10 nM Kp-10 also resulted in
increased phosphorylation of EGFR, reaching a peak between 5
and 15 min post-treatment (Fig. 4B) although the Hs578T cells
express less EGFR in contrast to MDA-MB-231 cells (Fig. S1A).
Both of these invasive breast cancer cell lines exhibit basal EGFR
phosphorylation (Fig. 4A, 4B). Thus, our results show for the first
time that Kp-10 signaling via endogenous GPR54 leads to the
transactivation of endogenous EGFR in breast cancer cells.
Since Kp-10 treatment promotes MMP-9 secretion and activity in
MDA-MB-231 cells that express endogenous GPR54 [27] (Fig. 2D),
Figure 5. Kp-10-induced breast cancer cell invasion requires b-arrestin 2. (A) MDA-MB-231 cells stably expressing scrambled shRNA controls
and b-arrestin 2 shRNA were plated in serum-free medium or serum-free medium containing 10 nM Kp-10 and allowed to invade for 20 h towards
media with 10% serum. Kp-10 treatment (10 nM) significantly increased invasion of cells expressing scrambled control towards 10% serum
(*, P,0.05). Depletion of b-arrestin 2 significantly inhibits invasion towards media with 10% serum when compared to Kp-10-treated control cells
(**, P,0.05). Columns represent mean percentage of cells invaded as compared to control cells invaded towards media with 10% serum 6 SEM. Data
from three independent experiments. (B) Depletion of b-arrestin 2 blocks MMP-9 secretion and activity in breast cancer cells. MDA-MB-231 cells stably
expressing scrambled control shRNA or b-arrestin 2 shRNA were treated for 48 h in Kp-10 in serum-free media. Overlaid media was then collected and
subjected to gelatin zymography. Data from five independent experiments. (C) Depletion of b-arrestin 2 inhibits Kp-10–mediated EGFR
phosphorylation in MDA-MB-231 cells. Cells were serum-starved for 24 h, treated with 10 nM Kp-10 for the indicated time points. Kp-10 treatment
results in a significant increase in EGFR phosphorylation in the scrambled controls, in contrast to b-arrestin 2 knockdown cells (One-way ANOVA
followed by Dunnett’s multiple comparison test: *, P,0.05). Basal levels of phosphorylated EGFR are regarded as 1. Columns represent relative fold
change of phosphorylated EGFR as compared to basal level 6 SEM. Data from three independent experiments.
doi:10.1371/journal.pone.0021599.g005
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EGFR by GPR54. We found that the activation of MMP-9 was
inhibited upon treatment of the cells with AG1468, an EGFR
inhibitor, indicating that Kp-10-induced MMP-9 activity was
dependent on the activation of EGFR (Fig. 4C). Furthermore, pre-
treatment of MDA-MB-231 FLAG-GPR54 cells with AG1478,
significantly decreased invasion when compared to untreated cells
(Fig. 4D), even in the presence of Kp-10. Thus Kp-10-induced
MMP-9activityrequiredforinvasionisdependentonEGFRactivity.
b-arrestin 2 is required for GPR54-mediated invasion
We have recently demonstrated that the GPCR adaptor
protein, b-arrestin, regulates MDA-MB-231 cell invasiveness
[23]. In addition, we found that GPR54, which is endogenously
expressed in MDA-MB-231 cells, was unable to stimulate ERK1/
2 activity, upon depletion of b-arrestin 2 [27]. This suggests that b-
arrestin 2 is required for GPR54 signaling to ERK1/2. To define a
molecular mechanism by which Kp-10 induces breast cancer cell
invasiveness, we investigated the effect of depleting b-arrestin 2 on
this process. Knockdown of b-arrestin 2 in MDA-MB-231 cells
significantly reduced basal invasion in the absence of Kp-10, as
well as Kp-10-stimulated invasion, compared with the scrambled
control shRNA (Fig. 5A). Furthermore, we found that depletion of
b-arrestin 2 reduced MMP-9 secretion and activity in cells, in the
presence or absence of Kp-10, in contrast to cells expressing the
scrambled control shRNA (Fig. 5B). Kp-10–mediated EGFR
phosphorylation was also inhibited in b-arrestin 2 knockdown
cells, as compared to the scrambled controls, implicating a role for
b-arrestin 2 in mediating Kp-10-induced EGFR transactivation
(Fig. 5C). Knockdown of b-arrestin 2 did not affect cell viability as
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assays (Fig. S1B). These results reveal that
b-arrestin 2 regulates basal and Kp-10-dependent invasion, by
regulating MMP-9 secretion and activity.
Although the details of the mechanism by which endogenous b-
arrestins regulate MMP activity is currently unknown, b-arrestins
can scaffold Src, shown previously to promote invasion via MMP-9
secretion in breast cancer cells [33,34]. However, we found that
knockdown of b-arrestin 2 expression had no effect on Src
activation in MDA-MB-231 cells (Fig. S2), implicating that other
pathways might be involved.
Kp-10 or EGF stimulates the internalization of GPR54 in
breast cancer cells
Our data so far indicates that GPR54 transactivates EGFR to
regulate breast cancer cell invasion. To better understand the
nature of the cross-talk between these two receptors, we sought
to determine whether or not Kp-10 or EGF can stimulate
GPR54 endocytosis in MDA-MB-231 FLAG-GPR54-expressing
cells. FLAG-GPR54 was localized at the cell surface in
unstimulated cells (Fig. 6-i). Treatment with 10 nM Kp-10 or
10 ng/mL EGF (Fig. 6-ii and -iii, respectively) resulted in
FLAG-GPR54 receptor internalization within 5 or 15 min of
stimulation to a peri-nuclear region. This demonstrated that
EGF, like Kp-10, induces the internalization of GPR54 in breast
cancer cells.
GPR54 associates with EGFR
We also determined whether or not GPR54 is able to interact
with EGFR using co-immunoprecipitation studies. We found that
FLAG-GPR54 interacts with EGFR in the absence of Kp-10 in
HEK 293 cells and that addition of Kp-10 (100 nM) increased the
amount of interaction of GPR54 with EGFR (Fig. 7A). To
determine whether or not GPR54 and EGFR are co-localized to
the same endocytotic vesicles upon internalization, we co-
expressed FLAG-GPR54 and EGFR-GFP in cells. In HEK 293
cells, both receptors were localized at the cell membranes (Fig. 7B-
i). Treatment of cells with either Kp-10 (Fig. 7B-ii) or EGF
(Fig. 7B-iii) resulted in partial co-localization of FLAG-GPR54
and EGFR-GFP in endocytotic vesicles. In unstimulated MDA-
MB-231 cells, FLAG-GPR54 and EGFR-GFP were primarily
localized to the cell membrane (Fig. 7C-i). Treatment with 10 nM
Kp-10 resulted in internalization of both FLAG-GPR54 and
EGFR-EGFP, with partial co-localization of the two receptors
upon Kp-10 treatment (Fig. 7C-ii). Similar observations were
made upon treatment of cells with EGF (data not shown).
GPR54 interacts directly with EGFR
To further confirm the interaction between GPR54 and EGFR,
and to study the nature of this interaction, we performed PFRET
on HEK 293 cells co-expressing GPR54-ECFP and EGFR-EGFP;
in all cases PFRET analysis was performed at the plasma
membrane. Our results confirmed our co-immunoprecipitation
Figure 6. Kp-10 and EGF induce internalization of GPR54 and EGFR in breast cancer cells. MDA-MB-231 cells stably expressing FLAG-
GPR54 were grown on glass coverslips and incubated in the absence (0 min) or presence of Kp-10 (10 nM) or EGF (10 ng/mL). Cells were then
subjected to immunofluorescence staining using a monoclonal FLAG antibody (red) and nuclei staining with 0.1% Hoechst 33258 dye (blue). Upon
treatment of cells with 10 nM Kp-10 (ii) or 10 ng/mL EGF (iii), FLAG-GPR54 internalized and was localized at peri-nuclear regions. Representative
confocal micrographs from five independent experiments are shown. Scale bar, 10 mm.
doi:10.1371/journal.pone.0021599.g006
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membrane of unstimulated cells expressing both receptors (Fig. 8).
These results indicate that GPR54 interacts directly with EGFR at
the plasma membrane even in the absence of agonist. Following
stimulation with Kp-10 (100 nM) or EGF (10 ng/ml), both
receptors remained associated with each other at the plasma
membrane; however, only stimulation with Kp-10 significantly
changed the average FRET efficiency values relative to that of
unstimulated cells upon 15 min of stimulation (Fig. 8A, B). Similar
results were obtained upon stimulation with 10 nM Kp-10 (data
not shown). To account for the reduction in fluorescence caused
by photobleaching of the fluorophores after repeated imaging of
the same set of cells, we performed control experiments with
unstimulated cells and imaged them at 5 and 15 min. The average
FRET efficiency values obtained from these controls were used to
normalize the data obtained in cells stimulated with Kp-10 and
EGF (Fig. 8A, B). We did not observe a significant amount of
FRET signal inside the cytoplasm of non-treated or agonist-
stimulated cells. Overall, these data indicate that GPR54 interacts
directly with EGFR in the presence or absence of agonist.
Discussion
Although recent studies indicate that Kp signaling may correlate
positively with breast tumor progression and metastatic potential
[10,11], it is unknown whether Kp stimulate breast cancer cell
invasiveness. Our data suggest that Kp-10/GPR54 signaling is
pro-migratory and pro-invasive in human breast cancer cells. We
show for the first time that Kp-10 stimulates breast cancer cell
invasion concomitant with MMP-9 secretion and activity, and
have implicated b-arrestin 2 in this process. We have also
discovered that GPR54 directly complexes with EGFR, and that
stimulation of breast cancer cells with either Kp-10 or EGF
regulates the endocytosis of both GPR54 and EGFR.
Significant progress has been made in understanding the complexity
of GPCR tyrosine kinase signaling over the last decade. Once seen as
isolated receptors connecting extracellular signals to the activation of G
proteins, GPCRs are now regarded as complex receptors capable of
initiating a vast array of signaling pathways, including G protein-
dependent and -independent signaling, binding various scaffolding
molecules, and interacting both directly and indirectly with other
receptor families. Several GPCRs have been shown to transactivate
EGFR and this plays important roles in not only normal physiological
functions, but also in pathophysiology [17,49–53].
Elevated expression of EGFR is associated with highly aggressive
and metastatic cancers, including cancer of the breast [35]. As a
member of the ErbB family of receptor tyrosine kinases, EGFR has
been characterized as a proto-oncogene. EGFR and other ErB
receptors may be upregulated or mutated in cancer and this results
in changes in downstream signaling partners which can contribute
to resistance mechanisms employed by cancer cells. This ability of
EGFR, to function despite treatment with tyrosine kinase inhibitors
and targeting antibodies, poses a major problem for cancer therapy
[35]. Thus, an understanding of EGFR signaling cascades is vital in
the production of specific therapies targeting metastasis.
Our findings reveal that unlike their role in other cancer cell
types, Kp-10 positively regulates breast cancer cell motility and
invasion. Kp-10 does not act as a chemoattractant but potentiates
invasion towards 10% serum. MDA-MB-231 and Hs578T cells
are negative for the expression of estrogen receptors; estrogen
receptor levels are used as a prognostic marker of breast tumors
[36]. We investigated the effects of Kp-10 on cell migration of
human T47D cells which also express KISS1 [10], but are positive
for estrogen and progesterone receptors. We found that Kp-10 (10
or 100 nM) did not stimulate T47D cell migration (Fig. S3A),
suggesting that Kp-10 may influence metastatic potential of the
more aggressive breast cancer cells that are deficient of hormone
receptors. Similarly, we found that Kp-10 (10 or 100 nM) did not
stimulate migration of the human malignant melanoma cells
C8161 (Fig. S3B), which have been previously used by Welch’s
group to study the anti-metastatic effects of Kp [1].
Figure 7. GPR54 associates with EGFR. (A) GPR54 co-immunopre-
cipitates EGFR in HEK 293 cells expressing FLAG-GPR54 and EGFR-GFP
in the presence or absence of Kp-10 (100 nM). Representative blot of
three independent experiments shown. (B) HEK 293 cells expressing
FLAG-GPR54 and EGFR-GFP were incubated in the absence (0 min, i) or
presence of Kp-10 (10 nM, ii) or EGF (10 ng/mL, iii) for 15 min. After
15 minutes of Kp-10 stimulation (ii), FLAG-GPR54 and EGFR-GFP
partially co-localized in endocytotic vesicles (yellow). Similar results
were obtained upon treatment of cells with 10 ng/mL EGF for
15 minutes (iii). Representative blot of three independent experiments
shown. Scale bar, 10 mm. C) MDA-MB-231 cells stably expressing FLAG-
GPR54 and EGFR-EGFP were incubated in the absence (0 min, i) or
presence of Kp-10 (10 nM) for 15 min (ii). Representative confocal
images of five experiments shown here. Scale bar, 10 mm.
doi:10.1371/journal.pone.0021599.g007
Kisspeptin Promotes Breast Cancer Invasion
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21599We further show that Kp-10-mediated activation of GPR54
enhances the invasive abilities of MDA-MB-231, MDA-MB-231
FLAG-GPR54, and Hs578T cells in 3D invasion assays. Kp-10
did not enhance invasion of breast cancer cells when EGFR was
inhibited through the use of tyrosine kinase inhibitor AG1478,
suggesting EGFR involvement in Kp-10-stimulated invasion.
Previous reports have shown that MDA-MB-231 invasion towards
EGF to be blocked by AG1478 [37]. We found that Kp-10
transactivates EGFR robustly in MDA-MB-231 cells and in
Hs578T cells that are less metastatic [38] and express significantly
less EGFR, as we and others have shown [39].
Ourdata revealsthat Kp-10 can stimulate invasiveness concomitant
with the production of MMP-9, and that this is dependent on EGFR
activation. To date, this is the first demonstration that Kp stimulate
MMPs. Conversely, it has been reported that in HT-1080 human
fibrosarcoma cells where Kp signaling is anti-invasive, expression of
KISS1 results in the negative regulation of MMP-9 production [9]. We
found that Kp-10-induced EGFR transactivation and invasion occur
via a b-arrestin 2-dependent mechanism. Furthermore, transactivation
of EGFR by GPR54 is required for the secretion and activation of
MMP-9 in addition to b-arrestin 2. We have recently shown that the
b-arrestins play important roles in regulating breast cancer cell
invasion towards the bioactive lipid lysophosphatidic acid via Ral
GTPases [23,40]. Several other studies have shown that b-arrestins
participate in tumor-related signaling pathways [41,42,43,44,45].
Recent work has shown that transgenic mice over-expressing b-
arrestin 1 resulted in rapid xenograft tumor progression due to
enhanced tumor angiogenesis, mediated by an increase in MMP-9
activity [45]. Therefore, b-arrestins may function as critical regulators
of tumor invasion and these studies are currently under investigation.
Kp-10 can stimulate cytoskeletal changes required for cell motility
via Rho GTPases [3]. A role for RhoA has been shown in regulating
cellmigration in highly aggressive cancer cellssuch as MDA-MB-231
and MDA-MB-435 [46]. Constitutively active Rho mutant V14 was
shown in MDA-MB-231 cells to not only increase basal migration,
but also to enhance basal EGFR activation [47]. Activation of RhoA
Figure 8. GPR54 interacts directly with EGFR. PFRET analysis of HEK 293 cells expressing GPR54-ECFP and EGFR-EGFP at the plasma membrane
before and after stimulation with (A) 100 nM Kp-10 and (B) 10 ng/ml EGF. Representative confocal micrographs are shown. Scale bar, 10 mm. The
images show the location of the 5 ROIs at the plasma membrane where FRET was analyzed. The left column show the localization of GPR54-ECFP, the
middle column shows the localization of EGFR-EGFP, and the right column shows the results for FRET efficiency after performing the PFRET analysis
using the sensitized emission method (see colour scale for reference). Columns represent mean PFRET values 6 SEM. Data from five independent
experiments.
doi:10.1371/journal.pone.0021599.g008
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induced cell retractile morphological changes, occurs upon EGF
treatment in EGFR-overexpressing cells [48]. Thus, Kp treatment of
MDA-MB-231 cells may promote migration by stimulating RhoA
activation and FAK dephosphorylation via EGFR.
We show for the first time that GPR54 directly interacts with
EGFR by PFRET usingthe sensitizedemission method. Our results
showthat the two receptors interact with eachother in unstimulated
cells, and this association occurs mainly at the plasma membrane.
Following agonist stimulation, a fraction of receptors continue to
associate at the plasma membrane, although we did observe
receptor internalization by confocal studies. The lack of a
substantial amount of FRET signal inside cells following agonist
stimulation could be due to the fact that the interaction between the
two receptors is no longer direct, once the receptors have
internalized. It is important to note that FRET methods based on
fluorescence intensity, such as the sensitized emission method that
we used in this study, cannot distinguish between a change in FRET
efficiency and a change in FRET population [49]. Therefore, a
reductioninthenumberofreceptormolecules presentattheplasma
membrane due to agonist-stimulated internalization would not
affectthe average FRET values. Furthermore,theabsence ofFRET
does not provide proof for the absence of an interaction, since there
are a number of factors that can affect the results, such as a change
in the physical structure of the receptor molecules that would
separate the donor and acceptor moieties or movement of the
receptor molecules as they internalize out of the focal plane [50].
To date, a limited number of GPCRs have been shown to interact
(directly or indirectly) with EGFR. Recently, it was discovered that
the vasopressin 1A receptor, a Gq–coupled receptor also interacts
with EGFR by co-immunoprecipitation studies, although how this
interaction affects signaling of either receptor is unknown [51]. The
b1-adrenergic receptor has been shown to interact with EGFR by co-
immunoprecipitation and FRET analysis under basal conditions
[52]. Treatment of cells with the b1- adrenergic receptor agonist,
isoproterenol, did not affect FRET efficiency when compared to
untreated cells[52].WealsofoundthatEGF treatmentpromotedthe
internalization of GPR54 in breast cancer cells and that GPR54 and
EGFR partially co-localized upon treatment of Kp-10 or EGF.
Similar observations have been reported with b2-adrenergic receptor
which co-localized with EGFR in response to isoproterenol
stimulation [53]. Thus, although many GPCRs can transactivate
EGFR [16,54,55], the association with EGFR appears to be unique
to a subset of GPCRs. For example, activation of the angiotensin
receptor(AT1AR)canalsotransactivateEGFR, howeverthisreceptor
does not complex with EGFR [52].
Targeted therapies against EGFR in cancer treatment have
been disappointing due to the robust nature of EGFR signalling.
Our work provides the first evidence that GPR54 signaling
positively regulates breast cancer cell invasiveness, via EGFR
crosstalk that involves MMPs and b-arrestin 2. Currently, ongoing
studies are looking to identify the binding domains between both
receptors, and to further examine the nature of the crosstalk.
Elucidation of novel signaling pathways may uncover new drug
targets.
Supporting Information
Figure S1 EGFR expression in breast cancer cells and
cell viability assays. (A) Comparison of total EGFR expression
in Hs678T, MDA-MB-231 and FLAG-GPR54 MDA-MD-231 by
Western blot analysis. Data from three independent experiments.
(B) Knockdown of b-arrestin 2 does not affect cell viability as
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assays. Data from three independent
experiments.
(TIF)
Figure S2 The effect of b-arrestin 2 knockdown on Src
phosphorylation. Depletion of b-arrestin 2 has no effect on the
change in Src phosphorylation (phospho-Src family Tyr416,
1:1000, Cell Signaling Technology) levels in MDA-MB-231 b-
arrestin 2 knockdown cells when compared to the MDA-MB-231
scrambled. MDA-MB-231 scrambled and MDA-MB-231 b-
arrestin 2 knockdown were serum-starved for 24 h, treated with
10 nM Kp-10 for the indicated time points. Densitometric analysis
of western blots revealed that following Kp-10 treatment there was
no change in Src phosphorylation in the scrambled controls or in
the MDA-MB-231 b-arrestin 2 knockdown cells. Basal levels of
phosphorylated Src are regarded as 1. Columns represent relative
fold change of phosphorylated EGFR as compared to basal level
6 SEM. Data from three independent experiments.
(TIF)
Figure S3 The effect of Kp-10 on T47D and C8161 cell
migration. Kp-10 does not stimulate migration of (A) T47D
breast cancer cell or (B) C8161 invasive melanoma cells as
measured by Transwell chamber assays. Data from six indepen-
dent experiments.
(TIF)
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